Alefacept

Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc.(http://www.amevive.com/Patient%20letter.pdf), the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of FDA-mandated or voluntary product recall. On the other hand, using of Amevive was associated with a certain risk of development systemic diseases such as malignancies and this drug was never approved for the European drug market.

Alefacept is used to control inflammation in moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation. It is also being studied in the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma.

Alefacept is a fusion protein: it combines part of an antibody with a protein that blocks the growth of some types of T cells.

Read more about Alefacept:  Mode of Action, Indications, Contraindications and Precautions, Pregnancy and Lactation, Pediatric Patients, Side Effects, Interactions, Necessary Laboratory Examinations, Dosage Regimes